Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 5:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Schizophrenia Spectrum Clear all
Recruiting Not applicable Interventional

CBT-CP for Veterans With SMI

NCT06758414
View directory record Official record
Conditions
Chronic Pain, Schizophrenia, Psychotic Disorders, Bipolar Disorder, Affective Disorders, Psychotic
Interventions
Cognitive Behavioral Therapy for Chronic Pain (CBT-CP), Health & Wellness (H&W)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 28, 2026, 5:06 PM EDT
Not listed No phase listed Observational

Schizophrenia and PTSD Project: Health, Interventions, and Risk/Resilience Evaluation(SAPPHIRE Study)

NCT00560677
View directory record Official record
Conditions
Schizophrenia, PTSD
Interventions
Not listed
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years to 72 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Sep 28, 2026, 5:06 PM EDT
Terminated Phase 1 Interventional

Alexithymia Intervention for Suicide

NCT05724953
View directory record Official record
Conditions
Suicide, Schizophrenia, Bipolar Disorder, Post Traumatic Stress Disorder, Major Depressive Disorder
Interventions
Affective Awareness
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Not applicable Interventional

Increasing Medication Check Participation Through Applying CT-r

NCT06231407
View directory record Official record
Conditions
Schizophrenia and Related Disorders
Interventions
Recovery Oriented CBTp Medication Management, Treatment as Usual
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 28, 2026, 5:06 PM EDT
Completed No phase listed Observational

Pediatric Bipolar Registry

NCT02360267
View directory record Official record
Conditions
Bipolar Disorder, Depression, Mania, Psychosis
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
6 Years to 17 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 1Phase 2 Interventional

Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia

NCT01292577
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
CET/PT, Treatment as Usual
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2020 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Not applicable Interventional

Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia

NCT00161031
View directory record Official record
Conditions
Schizophrenia
Interventions
Atomoxetine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Baltimore, Maryland • Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2019 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Not applicable Interventional

A Comparative Study of New Medications for Psychosis in Adolescents

NCT00222495
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorders
Interventions
quetiapine, olanzapine, risperidone
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 10, 2006 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Not applicable Interventional Results available

Using Digital Media Advertising to Reduce the Duration of Untreated Psychosis

NCT03975400
View directory record Official record
Conditions
Schizophrenia, First Episode Psychosis
Interventions
search engine advertisement campaign
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
Not listed
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Glen Oaks, New York • Queens, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 1 Interventional Results available

CVN058 Effect on Mismatch Negativity in Schizophrenics

NCT03669250
View directory record Official record
Conditions
Schizophrenia
Interventions
CVN058, Placebo comparator
Drug · Other
Lead sponsor
Cerevance Alpha, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Sep 28, 2026, 5:06 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

NCT05184335
View directory record Official record
Conditions
Schizophrenia
Interventions
Brilaroxazine, Placebo
Drug · Other
Lead sponsor
Reviva Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
690 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Bentonville, Arkansas • Little Rock, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Get Moving and Get Well - Pilot Study

NCT01884025
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression, Post Traumatic Stress Disorder
Interventions
Get Moving and Get Well, Health and Humor Class
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
North Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2018 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Not applicable Interventional

Examining Persistence in Smokers With Schizophrenia

NCT03346291
View directory record Official record
Conditions
Smoking Cessation, Schizophrenia, Schizo Affective Disorder
Interventions
counseling
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 64 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Sep 28, 2026, 5:06 PM EDT
Not yet recruiting Phase 4 Interventional

An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With Schizophrenia

NCT06924255
View directory record Official record
Conditions
Schizophrenia Disorders
Interventions
Xanomeline and Trospium Chloride
Drug
Lead sponsor
Collaborative Neuroscience Research, LLC
Network
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
7
States / cities
Bellflower, California • Garden Grove, California • Riverside, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Sep 28, 2026, 5:06 PM EDT
Completed No phase listed Observational

The Assessment of Movement Disorders Utilizing Live Two-Way Video

NCT01467089
View directory record Official record
Conditions
Tardive Dyskinesia
Interventions
Two way video assessment
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia

NCT03323437
View directory record Official record
Conditions
Schizophrenia Spectrum and Other Psychotic Disorders
Interventions
Risperidone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 35 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2024 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Acute Glycine Pharmacodynamic Study

NCT01610011
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Glycine administration
Dietary Supplement
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 26, 2015 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Integrated Care (IC) Models for Patient-Centered Outcomes

NCT03451630
View directory record Official record
Conditions
Diabetes, Asthma, Chronic Obstructive Pulmonary Disease, Hypertension, Anxiety, Atrial Fibrillation, Congestive Heart Failure, Depression, Bipolar Disorder, Schizophrenia
Interventions
High-Touch, High-Tech, Optimal Discharge Planning
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years and older
Enrollment
1,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Sep 28, 2026, 5:06 PM EDT
Terminated Not applicable Interventional

Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents

NCT00183612
View directory record Official record
Conditions
Bipolar Disorder, Psychotic Disorders
Interventions
Olanzapine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 18 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
2
States / cities
Belmont, Massachusetts • Medford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Sep 28, 2026, 5:06 PM EDT
Completed No phase listed Observational

fMRI Study of Nicotinic Effect on Neurophysiology of Schizophrenia

NCT01046526
View directory record Official record
Conditions
Schizophrenia, Psychopathology, Nicotine Dependence
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Not applicable Interventional Results available

Integrated Smoking Cessation Treatment for Smokers With Serious Mental Illness

NCT02845440
View directory record Official record
Conditions
Cigarette Smoking, Schizophrenia, Bipolar Disorder, Depressive Disorder, Major, Smoking Cessation
Interventions
Academic Detailing, Community Health Worker, Treatment as Usual (TAU)
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 1 Interventional

Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia

NCT00876304
View directory record Official record
Conditions
Schizophrenia
Interventions
PF-04802540, Placebo
Drug
Lead sponsor
Taisho Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2010 · Synced Sep 28, 2026, 5:06 PM EDT
Active, not recruiting Not applicable Interventional

EPI-MINN: Targeting Cognition and Motivation - National

NCT05877716
View directory record Official record
Conditions
Psychosis, Psychosis Nos/Other, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Prodromal Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizophreniform Disorders, Major Depression With Psychotic Features, Unspecified Psychosis, Bipolar Disorder
Interventions
Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care
Device · Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 40 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Vabicaserin in Subjects With Schizophrenia

NCT00563706
View directory record Official record
Conditions
Schizophrenia
Interventions
vabicaserin, risperidone, placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
32
States / cities
Little Rock, Arkansas • Cerritos, California • Escondido, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2014 · Synced Sep 28, 2026, 5:06 PM EDT